Ligand-Modulated Regulation of Progesterone Receptor Messenger Ribonucleic Acid and Protein in Human Breast Cancer Cell Lines
- 1 March 1988
- journal article
- research article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 2 (3), 263-271
- https://doi.org/10.1210/mend-2-3-263
Abstract
We gave examined the effects of estrogen and progestin agonist and antagonist ligands on regulation of progesterone receptor (PR) protein and mRNA levels in a variety of human breast cancer cell lines. By Northern blot analysis, using human PR cDNA probes, PR mRNA in T47D and MCF-7 cells appears as five species of approximately 11.4, 5.8, 5.3, 3.5, and 2.8 kilobases. PR mRNA species are not detected in the PR protein-negative breast cancer cell lines MDA-MB-231 and LY2. T47D cells contain high levels of PR mRNA and protein (detected by hormone binding assay or Western blot analysis), and the PR protein and mRNA content of T47D cells are reduced to about 10% of the control level within 48 h of treatment with 10 nM promegestone; 17, 21-dimethyl-10-nor-pregna-4,9-diene-3, 20-dione (R5020) or 16.alpha.-ethyl-21-hydroxy-19-nor-pregn-4-ene-3,20-dione (ORG2058), both potent progestins. In contrast, teratment of T47D cells with the antiprogestin 17.beta.-hdyroxy-11.beta.-[4-dimethylaminophenyl]-17.alpha.-(1-propynyl)-estra-4, 9-dien-3-one) (RU38486) reduces PR protein and mRNA levels only transiently. PR protein and mRNA are virtually undetectable in control MCF-7 cells grown in the absence of estrogens. When estradiol is administered to MCF-7 cells, the PR mRNA and protein levels increase gradually and proportionately (10- or 40-fold, respectively, in 3 days). This estradiol stimulation of PR iIs repressed to basal levels if MCF-7 cells receive a 100-fold excess of the antiestrogen 6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-[2-1-pyrrolidinyl)ethoxy]phenylketone; LY 117018) concomitantly. After estrogen stimulation of PR in MCF-7 cells, treatment with R5020 or RU38486 results in a ca. 50% decrease in PR protein and mRNA content by 2 days. These studies reveal a close correspondence between changes in PR mRNA content and the PR protein content of cells in response to estrogen, antiestrogen, progestin, or antiprogestin exposure, suggesting that the changes in cellular PR protein are accounted for predominantly by changes at the transcriptional (RNA) level.Keywords
This publication has 16 references indexed in Scilit:
- Dynamics of Estrogen Receptor Turnover in Uterine Cellsin Vitroand in Uteriin Vivo*Endocrinology, 1986
- Progesterone receptor synthesis and degradation in MCF-7 human breast cancer cells as studied by dense amino acid incorporation. Evidence for a non-hormone binding receptor precursor.Journal of Biological Chemistry, 1986
- Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture.Proceedings of the National Academy of Sciences, 1986
- Selection and Characterization of a Breast Cancer Cell Line Resistant to the Antiestrogen LY 117018Endocrinology, 1985
- Genomic sequencing.Proceedings of the National Academy of Sciences, 1984
- CHARACTERIZATION AND QUANTITATION OF ANTI-ESTROGEN BINDING-SITES IN ESTROGEN RECEPTOR-POSITIVE AND RECEPTOR-NEGATIVE HUMAN-BREAST CANCER CELL-LINES1983
- Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistanceCell, 1982
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979
- STEROID RECEPTOR ANALYSES OF 9 HUMAN BREAST-CANCER CELL LINES1978
- A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acidBiochemical Journal, 1956